Literature DB >> 26947918

Morphometric analysis of gray matter integrity in individuals with early-treated phenylketonuria.

Shawn E Christ1, Mason H Price2, Kimberly E Bodner2, Christopher Saville2, Amanda J Moffitt3, Dawn Peck4.   

Abstract

The most widely-reported neurologic finding in individuals with early-treated phenylketonuria (PKU) is abnormality in the white matter of the brain. In contrast, much less is known regarding the impact of PKU on cortical gray matter (GM) structures. Presently, we applied advanced morphometric methods to the analysis of high-resolution structural MRI images from a sample of 19 individuals with early-treated PKU and an age- and gender-matched comparison group of 22 healthy individuals without PKU. Data analysis revealed decreased GM volume in parietal cortex for the PKU group compared with the non-PKU group. A similar trend was observed for occipital GM volume. There was no evidence of group-related differences in frontal or temporal GM volume. Within the PKU group, we also found a significant relationship between blood phenylalanine levels and GM volume for select posterior cortical sub-regions. Taken together with previous research on white matter and gray matter abnormalities in PKU, the present findings point to the posterior cortices as the primary site of neurostructural changes related to early-treated PKU.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain morphometry; Cerebral cortex; Gray matter; Magnetic resonance imaging; Phenylketonuria

Mesh:

Substances:

Year:  2016        PMID: 26947918     DOI: 10.1016/j.ymgme.2016.02.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  12 in total

1.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

Review 2.  Genetic etiology and clinical challenges of phenylketonuria.

Authors:  Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara
Journal:  Hum Genomics       Date:  2022-07-19       Impact factor: 6.481

3.  Creatine nanoliposome reverts the HPA-induced damage in complex II-III activity of the rats' cerebral cortex.

Authors:  Nathana Jamille Mezzomo; Diego Becker Borin; Francine Ianiski; Barbara Dotto Fontana; Itiane Diehl de Franceschi; Juliane Bolzan; Renata Garcez; Mateus Grings; Belisa Parmeggiani; Liana da Silva Fernandes; Rodrigo de Almeida Vaucher; Guilhian Leipnitz; Clovis Milton Duval Wannmacher; Virginia Cielo Rech
Journal:  Mol Biol Rep       Date:  2019-08-13       Impact factor: 2.316

Review 4.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

5.  Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria.

Authors:  Zoë Hawks; Joshua Shimony; Jerrel Rutlin; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab Rep       Date:  2017-02-23

6.  Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?

Authors:  Danique van Vliet; Annemiek M J van Wegberg; Kirsten Ahring; Miroslaw Bik-Multanowski; Kari Casas; Bozena Didycz; Maja Djordjevic; Jozef L Hertecant; Vincenzo Leuzzi; Per Mathisen; Francesca Nardecchia; Kimberly K Powell; Frank Rutsch; Maja Stojiljkovic; Fritz K Trefz; Natalia Usurelu; Callum Wilson; Clara D van Karnebeek; William B Hanley; Francjan J van Spronsen
Journal:  Nutrients       Date:  2019-10-25       Impact factor: 5.717

7.  Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.

Authors:  Roman Trepp; Raphaela Muri; Stephanie Abgottspon; Lenka Bosanska; Michel Hochuli; Johannes Slotboom; Christian Rummel; Roland Kreis; Regula Everts
Journal:  Trials       Date:  2020-02-13       Impact factor: 2.279

8.  A Retrospective Case Series Analysis of the Relationship Between Phenylalanine: Tyrosine Ratio and Cerebral Glucose Metabolism in Classical Phenylketonuria and Hyperphenylalaninemia.

Authors:  Colm J McGinnity; Daniela A Riaño Barros; Eric Guedj; Nadine Girard; Christopher Symeon; Helen Walker; Sally F Barrington; Mary Summers; Mervi Pitkanen; Yusof Rahman
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

9.  White and gray matter brain development in children and young adults with phenylketonuria.

Authors:  Zoë Hawks; Anna M Hood; Dov B Lerman-Sinkoff; Joshua S Shimony; Jerrel Rutlin; Daniel Lagoni; Dorothy K Grange; Desirée A White
Journal:  Neuroimage Clin       Date:  2019-07-02       Impact factor: 4.881

10.  A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing.

Authors:  Erik A Koppes; Bethany K Redel; Marie A Johnson; Kristen J Skvorak; Lina Ghaloul-Gonzalez; Megan E Yates; Dale W Lewis; Susanne M Gollin; Yijen L Wu; Shawn E Christ; Martine Yerle; Angela Leshinski; Lee D Spate; Joshua A Benne; Stephanie L Murphy; Melissa S Samuel; Eric M Walters; Sarah A Hansen; Kevin D Wells; Uta Lichter-Konecki; Robert A Wagner; Joseph T Newsome; Steven F Dobrowolski; Jerry Vockley; Randall S Prather; Robert D Nicholls
Journal:  JCI Insight       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.